Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

Hypertension Clinical Trial

— NECTAR III  

Official title:

Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR III Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05363761
• Other study ID #: PR 2012
• Status: Recruiting
• Phase: Phase 1
• Start date: April 19, 2022
• Est. completion date: January 2029

Study information

• Verified date: March 2023
• Source: Neurotronic, Inc.
• Contact: Yunlong Zhang, MD
• Phone: +1 669-203-9308
• Email: pzhang[@]libramed.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.

Description:

This study is a prospective, single-arm, multi-center trial to evaluate the safety and performance of use of the Neurotronic Infusion Catheter for chemical denervation of renal and hepatic arteries for treatment of patients with type 2 diabetes, hypertension, and obesity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: January 2029
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for participation in the study:

1. Age = 21 and = 65 years at time of enrollment.

2. Disease diagnosed

2.1 Diagnosed with T2DM with baseline:

1. Fasting plasma glucose = 140 mg/dl (7.8 mmol/l) and = 270 mg/dL (15 mmol/L)

2. HbA1c levels = 7.0% and = 9.0% (53-75 mmol/mol)

3. Triglyceride level < 400 mg/dL (4.52 mmol/L)

4. On oral anti-hyperglycemic drug regimen of metformin. Subjects may be on additional oral anti-hyperglycemic drug of a different drug class

5. Years of T2DM = 10 years

And / Or

2.2 Diagnosed hypertension with baseline:

1. Office blood pressure of SBP of = 140 mmHg and = 180 mmHg and DBP = 90 mmHg

2. Mean 24-hour ambulatory SBP of = 130 mmHg and = 170 mmHg with = 75% valid readings

3. On stable oral anti-hypertension drug regimen consisting of up to a maximum of three drugs

3. BMI between 27.5 and 40 kg/m2

4. C-peptide testing: non-fasting random or stimulated C-peptide = 2 ng/mL (660 pmol/L)

5. Vessel diameter of 3 mm to 7 mm with a minimum arterial treatable length of 20 mm in one or more of the following arteries:

• Renal

• Hepatic

Exclusion Criteria:

1. T1DM or poorly controlled T2DM (defined as HbA1c > 9.0% or use insulin as medication to control glucose level).

2. Office diastolic blood pressure < 90 mmHg.

3. Current use of > 3 hypertension medications.

4. Currently on beta blockers.

5. One or more documented hyperglycemia episodes requiring hospitalization in the 180-day prior to screening date.

6. Prior evidence of hypoglycemia unawareness or serious hypoglycemia with loss of consciousness or confusion sufficient to prevent self-treatment in last 6 months.

7. BMI > 40 kg/m2.

8. Diagnosed proliferative retinopathy or evidence of peripheral neuropathy.

9. Lack of appropriate treatment site or anatomy precluding the intervention of the target arteries (renal and hepatic artery).

10. History of prior renal or hepatic artery intervention including balloon angioplasty, stenting, etc.

11. Arterial stenosis >50% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment).

12. Any abnormality or disease in one or more of the target arteries that, per the physician assessment, precludes the safe insertion of the guiding catheter (including, but not limited to, artery aneurysm, excessive tortuosity, calcification).

13. Occlusive peripheral vascular disease that would preclude percutaneous femoral access for the procedure.

14. Known or suspected secondary hypertension, such as Cushing's disease or Cushing's Syndrome, hyperaldosteronism, pheochromocytoma, thyroid and parathyroid abnormalities, history of pre-eclampsia, onset of hypertension prior to the age of 18.

15. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.

16. Severe or unstable cardiovascular comorbidities, such as AMI or ACS, cardiac valve stenosis, pulmonary embolism, heart failure with NYHA Class III or IV, chronic atrial fibrillation, primary pulmonary hypertension, COPD.

17. Renal transplant, history of nephrectomy or single kidney, renal tumor/cancer, known non-functioning kidney, unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function), chronic renal deficiency with eGFR = 60ml/min/1.73m2, or on chronic renal replacement therapy.

18. Prior liver transplant.

19. Any organ transplantation procedures are planned in the 365 days following Index Procedure.

20. Gastrointestinal permanent anatomic alteration surgery.

21. Any surgical procedure within 30 days prior to Index Procedure.

22. Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study:

1. Systemic Corticosteroids

2. Anticonvulsants

3. Centrally acting sympatholytics

23. Bleeding disorders, such as bleeding diathesis, thrombocytopenia, and severe anemia.

24. Use of anticoagulation therapy which cannot be discontinued from 7 days before or 14 days after the Index Procedure.

25. Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the investigator.

26. Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake.

27. Active substance abuse, based on Investigator judgement, including inhaled or injected drugs, within 1 year prior to the initial screening.

28. Significant weight loss within the last 6 months (e.g., > 10% total body weight loss).

29. Hepatic decompensation defined as the presence of any of the following:

1. Serum albumin less than 3.5 g/dL

2. International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants)

3. Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome

4. History of esophageal varices, ascites, or hepatic encephalopathy

30. ALT or AST greater than 200 U/L.

31. Diagnosis of liver cirrhosis.

32. Chronic liver or biliary disease of the following etiology:

1. History or diagnosis of Hepatitis B

2. History or diagnosis of Hepatitis C

3. History or diagnosis of current active autoimmune hepatitis

4. History or diagnosis of primary biliary cholangitis

5. History or diagnosis of primary sclerosing cholangitis

6. History or diagnosis of Wilson's disease

7. History or diagnosis of alpha-1-antitrypsin deficiency

8. History or diagnosis of hemochromatosis

9. History or diagnosis of drug-induced liver disease, as defined on the basis of typical exposure and history.

10. Known bile duct obstruction.

11. Suspected or proven liver cancer

33. History of acute or chronic pancreatitis.

34. Human immunodeficiency virus (HIV).

35. Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT).

36. Systemic infection that the investigator judges would pose unacceptable procedural risks to the subject.

37. Known hypersensitivity to contrast media, nickel and ethanol that cannot be adequately pre-medicated.

38. Subject is depressed or on antidepressants.

39. Pregnancy or breastfeeding or plan to get pregnant in next 12 months.

40. Life expectancy of less than 5 years.

41. Unwilling or unable to comply with the follow-up study requirements.

42. Subjects or their legally authorized representatives unable to provide informed consent.

43. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.

44. Currently participation in another pre-market drug or medical device clinical study.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Hypertension

Intervention

Combination Product:
• Neurotronic Infusion Catheter
Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter

Locations

Country	Name	City	State
Panama	Hospital Paitilla Clinicas y Hospitales	Panamá
Panama	Hospital Punta Pacifica	Panamá
Paraguay	Sanatorio Adventista de Asunción	Asunción

Sponsors (2)

Lead Sponsor	Collaborator
Neurotronic, Inc.	Libra Medical

Countries where clinical trial is conducted

Panama,  Paraguay, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of serious device- and procedure-related complications at 30 days post procedure.	This composite endpoint is defined as: death; flow-limiting dissection at one or more of the treated arteries requiring intervention.; Type III perforation of the treated artery requiring intervention.; bleeding requiring transfusion.; severe or occlusive thrombosis of the treated artery beds; clinically significant distal embolization of the treated artery beds; clinically significant damage to kidneys and/or liver	30 Days
Primary	Device success	The device success, defined as successful introduction of the catheter, navigation to the treatment site, and infusion of the chemical to the perivascular without device malfunction that requiring aborting the procedure.	During the procedure
Secondary	Glycemic Control:	Change of fasting glucose and HbA1c will be analyzed by absolute and relative changes. Percent subjects with decreased fasting glucose and HbA1c will also be analyzed.	1 month, 3 months, 6 months, 12 months, and 24 months. Optional 3, 4 and 5 years to understand the long-term effects of the treatment.
Secondary	Hypertension Control:	Change of blood pressure will be analyzed by systolic, diastolic, and mean arterial pressure, absolute and relative changes of ABPM and office blood pressure. Percent subjects with decrease blood pressure will also be analyzed.	1 month, 3 months, 6 months, 12 months, and 24 months. Optional 3, 4 and 5 years